Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 36Gastrointestinal 18CNS 7Thoracic 6Breast 6Endocrine 5Tumor-Agnostic 4Head & Neck 4Gynecologic 4Sarcoma 3Dermatologic 3Plasma cell 2Other solid neoplasm 2NET 2Other hematologic neoplasm 1

Conditions

Triple Negative Breast Neoplasms 1Mesothelioma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Malignant Solid Neoplasm 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × cabozantinib × Other solid neoplasm × Clear all
NCT05038839 2026-05-12

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
44 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Calithera Biosciences, Inc

Phase 1 Completed
210 enrolled
BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡